Revolution Medicines (RVMD) CEO Mark Goldsmith Sells 86,000 Shares

What Happened

• Mark A. Goldsmith, President and Chief Executive Officer of Revolution Medicines (RVMD), reported multiple transactions on 2026-08-21. He exercised options to acquire 80,000 shares at $4.73 per share (cost $378,400) and reported an additional 80,000-share derivative conversion (reported as disposed at $0.00). He sold a total of 86,000 shares in open-market transactions at prices in the ~$207–$212 range, generating approximately $18.0 million in gross proceeds. The sales were made under a pre-established 10b5-1 trading plan.

Key Details

• Transaction date: August 21, 2026 (reported on Form 4 filed Aug 25, 2026).
• Option exercise: 80,000 shares acquired at $4.73 each; cash paid $378,400 (Code M).
• Open-market sales: 86,000 shares sold in multiple trades; total proceeds ≈ $17.99M. Reported per-trade weighted-average prices ranged roughly $206.78–$212.74 (see filing footnotes for ranges).
• Additional derivative entry: 80,000 shares reported as disposed at $0.00 (derivative transaction).
• Notable footnote: Sales were made pursuant to a 10b5-1 trading plan adopted May 22, 2026 (Footnote F1).
• Shares owned after the transactions: not specified in the summary provided; filing notes include 182,938 restricted stock units (footnote F2).
• Filing timeliness: Form 4 was filed Aug 25 for transactions on Aug 21; the filing does not state a late-filing designation.

Context

• The filing shows exercise of options followed by same-day open-market sales — a common pattern where exercised shares are sold (often to cover exercise cost/taxes or as planned sales). Transaction codes: M = option exercise/conversion, S = sale.
• The 10b5-1 plan notation indicates the sales were executed under a pre-arranged trading plan, which is typically used to avoid accusations of trading on nonpublic information. The filing is factual and does not state the insider’s motivations.